Investment & Milestones

ConfluxMind is a strict B2B Enterprise SaaS platform selling directly to clinics, medical groups, and the NHS.

Raising £750K Seed at a £2.5M Pre-Money Valuation (~$3.2M USD)

We are executing a milestone-based funding strategy. Investors can fund specific feature tranches that immediately unlock new B2B contract tiers and generate market-viable products at every stage.

Request Pitch Deck & Financial Model

Funding Milestones & Market Viability

Each funding milestone fully finances the development, compliance, and clinical testing of distinct product tiers. Timelines are relative to the start of funding, with features developed concurrently where possible.

Milestone 1: Core Clinical B2B

Ask: £150,000Equity: 6.0%

Timeline: Months 1–6

Feature 1: Intelligent Web App (£60K)Patient accounts, persistent conversational memory, and baseline clinical safety guardrails.

Feature 2: Clinical Dashboard (£90K)Enterprise portal for therapists/doctors to monitor patient progress, view AI insights, and integrate with clinical workflows.

Unlocks: Initial B2B Pilot Contracts

Milestone 2: Omnichannel Care

Ask: £250,000Equity: 10.0%

Timeline: Months 3–9 (Concurrent)

Feature 3: Native Mobile App (£100K)iOS/Android companion for on-the-go crisis management and skill practice.

Feature 4: Real-Time Voice (£80K)Conversational voice-chat integration for accessible, hands-free support.

Feature 5: Dynamic Avatars (£70K)User-selected or clinically-assigned personas/visuals to automatically adapt to patient needs and improve therapeutic alliance.

Unlocks: Mid-Market Clinic Sales

Milestone 3: Proprietary Scale

Ask: £350,000Equity: 14.0%

Timeline: Months 8–15

Feature 6: Custom Deep Model (£230K)Transition from third-party APIs to a proprietary, fine-tuned, clinically safe LLM hosted in-house (IP Moat).

Feature 7: Automated Check-ins (£120K)Proactive system where the AI initiates calls/texts to follow up on previous discussions and care plans.

Unlocks: NHS & Large Enterprise Tenders

The B2B Market

$7.5B TAM

Global mental health tech (2025), growing 16-17% CAGR.

$294M SAM

UK Clinical B2B Segment (2024), reaching $734M by 2030.

The Strategic Advantage: B2C mental health apps face crippling churn and massive customer acquisition costs (CAC). By selling directly to clinics (who distribute it free to patients), we achieve zero patient CAC, integrate directly into medical workflows, and lock in high-retention annual contracts.

B2B SaaS Unit Economics

Business ModelEnterprise Licensing
(Flat fee or Per-Seat)

Cost to End-Patient£0.00

Target ACV (Small Clinic)£12,000 / yr

Target ACV (Enterprise/NHS Trust)£50,000+ / yr

Gross Margin (Post-Milestone 3)~85%

Request B2B Financial Projections →

Cross-Border Founding Team

The founding team is designed to cover the three critical domains for a health-tech AI startup: regulatory/data governance, commercial strategy, and technical engineering.

CEO (Netherlands)

Data governance, regulatory compliance (GDPR, EU AI Act, MDR). Base provides direct EU market access.

CCO (United Kingdom)

Commercial strategy, investor relations, NHS and clinical partnerships, and B2B SaaS GTM execution.

CTO (United States)

AI engineering, prompt architecture, safety system design, and full product development stack.

Access the Data Room

We are currently engaging with B2B SaaS investors, health-tech angels, and clinical-first funds.

Request Stakeholder Toolkit Return to Home